TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Acquired by Amalgamated Bank

Amalgamated Bank raised its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 712.0% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 39,528 shares of the biopharmaceutical company's stock after buying an additional 34,660 shares during the quarter. Amalgamated Bank's holdings in TG Therapeutics were worth $925,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Swiss National Bank boosted its stake in TG Therapeutics by 0.5% during the first quarter. Swiss National Bank now owns 284,100 shares of the biopharmaceutical company's stock worth $4,321,000 after buying an additional 1,500 shares during the last quarter. Sei Investments Co. acquired a new position in shares of TG Therapeutics during the 1st quarter valued at about $591,000. Russell Investments Group Ltd. grew its holdings in shares of TG Therapeutics by 133.5% in the first quarter. Russell Investments Group Ltd. now owns 52,339 shares of the biopharmaceutical company's stock valued at $796,000 after purchasing an additional 29,923 shares during the period. ProShare Advisors LLC increased its position in TG Therapeutics by 8.5% during the first quarter. ProShare Advisors LLC now owns 24,914 shares of the biopharmaceutical company's stock worth $379,000 after purchasing an additional 1,961 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System raised its stake in TG Therapeutics by 10.5% during the first quarter. State Board of Administration of Florida Retirement System now owns 43,283 shares of the biopharmaceutical company's stock worth $651,000 after purchasing an additional 4,120 shares during the period. 58.58% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at TG Therapeutics

In other TG Therapeutics news, Director Sagar Lonial sold 5,000 shares of the company's stock in a transaction on Monday, November 11th. The shares were sold at an average price of $30.44, for a total transaction of $152,200.00. Following the completion of the transaction, the director now owns 100,195 shares in the company, valued at approximately $3,049,935.80. This represents a 4.75 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 10.50% of the company's stock.

TG Therapeutics Stock Down 4.2 %

Shares of NASDAQ:TGTX traded down $1.30 during trading hours on Friday, reaching $29.54. The stock had a trading volume of 3,274,962 shares, compared to its average volume of 3,708,598. The stock has a market capitalization of $4.60 billion, a price-to-earnings ratio of -295.37 and a beta of 2.19. The firm's 50 day moving average is $24.74 and its 200-day moving average is $21.07. TG Therapeutics, Inc. has a 1 year low of $10.98 and a 1 year high of $36.50. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing analysts' consensus estimates of $0.03 by ($0.01). TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The business had revenue of $83.90 million during the quarter, compared to analyst estimates of $81.68 million. During the same quarter in the prior year, the business earned $0.73 earnings per share. The firm's quarterly revenue was down 49.4% on a year-over-year basis. Research analysts predict that TG Therapeutics, Inc. will post 0.17 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on TGTX shares. B. Riley raised their price target on shares of TG Therapeutics from $29.00 to $34.00 and gave the stock a "buy" rating in a report on Wednesday, August 7th. HC Wainwright raised their target price on TG Therapeutics from $49.00 to $55.00 and gave the stock a "buy" rating in a research note on Tuesday, November 5th. TD Cowen started coverage on TG Therapeutics in a research note on Tuesday, October 29th. They issued a "buy" rating and a $50.00 price target on the stock. Finally, The Goldman Sachs Group raised their price objective on TG Therapeutics from $20.00 to $22.00 and gave the stock a "neutral" rating in a research report on Tuesday, November 5th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $37.67.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.